MDNA - Medicenna Therapeutics GAAP EPS of -$0.16 in-line

June, 27 2023 04:08 PM Medicenna Therapeutics Corp.

2023-06-27 16:08:56 ET

Medicenna Therapeutics press release ( NASDAQ: MDNA ): FY GAAP EPS of -$0.16 in-line.
As of March 31, 2023, cash and cash equivalents were $33.6 million, compared to $20.5 million on March 31, 2022. These funds are expected to provide the Company with sufficient capital to execute its current planned expenditures through the key milestones of the ABILITY study and through calendar Q3 2024 based on its current plans and projections.

For further details see:

Company Name:	Medicenna Therapeutics Corp.
Stock Symbol:	MDNA
Market:	NASDAQ